RT @drpnash: Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Re
Tweet Content
Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis https://t.co/1kqWeBcEDq #gca #GmCSFinh Novel MOA , big unmet need
Links
Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare…
https://acrabstracts.org/abstract/mavrilimumab-anti-gm-csf-receptor-%ce%b1-mono…
Show on Archive Page
On
Display in Search Results
On